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Abstract
Background: In Denmark and other countries, there has been a shift in the management of patients with
an implantable cardioverter defibrillator (ICD) with remote device monitoring largely replacing in-hospital
visits. Less patient-nurse and patient-physician interaction may lead to gaps in patients’ quality of care and
impede patients’ adaptation to living successfully with the ICD. A comprehensive eHealth intervention that
include goal-setting, monitoring of symptoms of depression, anxiety, and quality of life, psychological
treatment, information provision, supportive tools, online dialogues with nursing staff and access to an
online community network, may help fill these gaps and be particularly beneficial to patients who suffer
from anxiety and depression. This study will evaluate the effectiveness of the ACQUIRE-ICD care innovation,
a comprehensive and interactive eHealth intervention, on patient-reported and clinical outcomes.
Methods: The ACQUIRE-ICD study is a multicenter, prospective, two-arm, unblinded randomised controlled
superiority trial that will enroll 478 patients implanted with a first-time ICD or ICD with cardiac synchronisation therapy
(CRT-D) from the six implanting centers in Denmark. The trial will evaluate the clinical effectiveness and cost-effectiveness
of the ACQUIRE-ICD care innovation, as add-on to usual care compared with usual care alone. The primary endpoint,
device acceptance, assessed with the Florida Patient Acceptance Survey, is evaluated at 12 months’ post implant.
Secondary endpoints, evaluated at 12 and 24 months’ post implant, include patient-reported outcomes, return to work,
time to first ICD therapy and first hospitalisation, mortality and cost-effectiveness.
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Discussion: The effectiveness of a comprehensive and interactive eHealth intervention that relies on patient-centred and
personalised tools offered via a web-based platform targeted to patients with an ICD has not been assessed so far. The
ACQUIRE-ICD care innovation promotes and facilitates that patients become active participants in the management of
their disease, and as such addresses the need for a more patient-centered disease-management approach. If the care
innovation proves to be beneficial to patients, it may not only increase patient empowerment and quality of life but also
free up time for clinicians to care for more patients.
Trial registration: The trial has been registered on https://clinicaltrials.gov/ct2/show/NCT02976961 on November 30,
2016 with registration number [NCT02976961].
Keywords: Anxiety, Depression, Device acceptance, eHealth intervention, Heart disease, Implantable cardioverter
defibrillator, Patient-centered tools, Quality of life
Background
Implantable cardioverter defibrillator (ICD) therapy is
the first-line of treatment for the primary and secondary
prevention of sudden cardiac death [1]. Since the early
primary and secondary prevention trials were published
in the 1990’s, demonstrating risk reductions in mortality
ranging from 26% and higher, depending on the indica-
tion and sub-population [2, 3], the implantation rate has
increased substantially. The implantation rate now
seems to have stabilised in Western and Northern Euro-
pean countries, while the implantation rate has contin-
ued to rise in Eastern European countries [4]. In 2016,
the mean number of ICD implantations in Europe was
101 per million inhabitants [4].
The majority of patients implanted with an ICD do
well [5], despite ICD therapy being associated with risk
of procedural and device-related complications (e.g. in-
fection, lead dislocation, device and hardware malfunc-
tioning, and inappropriate shocks). However, a subset of
patients (20%) have difficulties with psychological adjust-
ment post implant and report significant levels of anx-
iety and depression and poor quality of life (QoL) [6, 7].
Poor patient-reported outcomes may in part be attrib-
uted to shocks and fear of shocks [8, 9], which may lead
to avoidance behaviours, a sedentary lifestyle, and sexual
problems. [10] However, other factors may play an equal
or larger role than ICD-related aspects. These include
the psychological profile of the patient (e.g. Type D per-
sonality [11, 12], lack of optimism [13]), illness percep-
tions [14], treatment expectations [15], and the underlying
disease (e.g. symptomatic heart failure) [16]. Managing pa-
tients’ psychological morbidity, although important, is
often ignored, even though depression and anxiety have
been associated with increased risk of mortality and in
some studies with ventricular tachyarrthmias despite
state-of-the-art treatment with the ICD [17–19].
In the last decade, we have witnessed a change in the
management of ICD patients, with face-to-face out-
patient visits largely being replaced by remote monitor-
ing [20], although variability exists between countries.
Remote monitoring enables the ICD clinic to detect ab-
normal heart rhythms and problems with the device fas-
ter, with demonstrated clinical and economic advantages
[21], although we know less about its impact on patients’
QoL. [22, 23] Despite the convincing clinical and eco-
nomic advantages this may have led to unrecognised
gaps in patients’ quality of care [24]. Due to less
patient-nurse and patient-physician interactions, it has
become more difficult to identify vulnerable patients
who need additional support and follow-up. This is fur-
ther complicated by the fact that in Denmark and many
other countries across the world, patients are not
screened for psychological morbidity as part of clinical
cardiology practice nor is any treatment for psycho-
logical morbidity available in the hospital setting. Pa-
tients may also be hesitant to contact the clinic outside
of scheduled visits in order not to burden the care team.
When examining patients’ preferences and needs for
care options that are not part of standard practice, the
majority of patients with ICD indicated that they would
have preferred to receive continuous feedback via re-
mote monitoring and also to have more interaction with
theire care team [24]. Taken together, this may impede
the transition to living successfully with the ICD for pa-
tients who have difficulties with psychological adjust-
ment after implant.
Intervention trials targeting symptoms of depression
and anxiety in the ICD population have largely used cog-
nitive behavioral therapy, relaxation and mindfulness
techniques, supplemented with telephone support, edu-
cation and exercise, and online therapies, as single,
one-time interventions [25, 26]. Although some of these
have shown promise, with the largest effects found for
cognitive behavioral therapy, the majority have been pla-
gued by methodological shortcomings and included rela-
tively small sample sizes [27–29]. The complexity of the
issues that patients with an ICD deal with may warrant a
more comprehensive intervention that is more
patient-tailored and facilitates patient empowerment. As
indicated by others, there is a need to continue to search
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for successful care modalities in order to ensure that pa-
tients are able to live the best possible life with their de-
vice and disease [30]. This requires “…a shift from
individual blame toward an empowerment and systems
approach that considers the big picture” [31].
One strategy for meeting these needs are asynchron-
ous, web-based strategies. Using an eHealth approach
that enables patients to interact at a time and place of
their convenience may have distinct advantages, in par-
ticular for patients who have to return to work after im-
plantation. Hence, to address these gaps in evidence and
clinical practice, we designed the ACQUIRE-ICD study
(A personalised and interactive web-based health care
innovation to AdvanCe the QUalIty of life and caRE of
patients with an Implantable Cardioverter Defibrillator).
A full description of the intervention is described in the
methods. ACQUIRE-ICD will formally evaluate the ef-
fectiveness of the comprehensive and interactive
ACQUIRE-ICD eHealth intervention on
patient-reported and clinical outcomes and the
cost-effectiveness as add-on to usual care as compared
to usual care alone.
Objectives
Primary objective
The primary objective is to investigate the effectiveness
of the comprehensive and interactive ACQUIRE-ICD
eHealth intervention as add-on to usual care as com-
pared to usual care alone on device acceptance, as mea-
sured by the Florida Patient Acceptance Scale, at
12 months post implant (the end of the intervention).
Secondary objectives
The secondary objectives are to investigate the effective-
ness of the ACQUIRE-ICD eHealth intervention on
health status (generic and disease-specific), patient em-
powerment, ICD concerns, anxiety, depression, return to
work, time to first ICD therapy defined as
anti-tachycardia pacing (ATP) or shock therapy, time to
first hospitalisation due to a cardiac cause, mortality,
and cost-effectiveness at 12 and 24 months post implant.
Methods
Study design
ACQUIRE-ICD is a multicenter, prospective, two-arm,
unblinded randomised controlled superiority trial that
will enroll patients receiving their first ICD or CRT-D
from the six ICD implanting centers in Denmark:
Odense University Hospital; Aarhus University Hos-
pital; Copenhagen University Hospital (Rigshospitalet);
Copenhagen University Hospital (Gentofte); Aalborg
University Hospital; Zealand University Hospital
(Roskilde).
Subjects and eligibility
A sample of 478 patients will be recruited consecu-
tively from the 6 participating centers. Patients are
eligible to participate if they fulfill all of the inclu-
sion criteria and none of the exclusion criteria, as
indicated in Fig. 1. The CONSORT guidelines for a
parallel-group randomised controlled trial will be
used when reporting on the results of the trial [32].
Patient recruitment
Patients will be asked if they wish to participate in
the study while hospitalised for their ICD implant-
ation. After screening for in- and exclusion criteria,
eligible patients will receive written and oral informa-
tion about the study and asked to sign an informed
consent form, if they agree to participate. The base-
line questionnaire is sent as a link to their personal
email and answered online in the Research Electronic
Data Capture (REDCap) database, either in hospital
or at home and between 48 h pre-implantation and 2
weeks post implantation. Once patients have the ICD
implanted and completed the baseline questionnaire,
they will be allocated to the interactive web-based
care innovation or usual care, with the use of the
random allocation sequence. Patients in the interven-
tion arm are given a 45-min introduction, either
face-to-face during hospitalisation or via telephone in
their home setting, how to access and use the
web-based platform. To ensure that there are no
technical problems and that patients are able to use
the platform, within the first week, they are asked to
write a message via the platform to the nurse
assigned to them from the implanting hospital.
Study endpoints
Primary endpoint
The primary endpoint is patient device acceptance
measured with the Florida Patient Acceptance Survey
[33, 34], evaluated at 12 months’ post implant.
Secondary endpoints
Secondary endpoints include health status (generic and
disease-specific), patient empowerment, ICD concerns,
anxiety, depression, return to work, time to first ICD
therapy defined as ATP or shock, time to first hospital-
isation due to a cardiac cause, mortality, resource use
and costs related to the intervention, additional health-
care resource use and costs during the observation
period, and cost-effectiveness. All secondary endpoints
are evaluated at 12 and 24 months’ post implant. Pri-
mary and secondary outcomes are presented in Table 1.
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Measures
Demographic and clinical variables
Information on patients’ demographic and clinical base-
line characteristics and follow-up events are captured
from patients’ electronic health records (EHRs) and en-
tered into REDCap. This information is registered for all
patients, both those who consent to participate, refuse
participation and drop out of the study, if they provide
written informed consent.
Patient-reported measures
An overview of the patient-reported measures and re-
lated measures and their time of administration are
shown in Table 2. All measures are standardised and val-
idated, although purpose-designed questions or ques-
tionnaires have been added if relevant and when no
validated measure was available (e.g. in relation to the
assessment of cost-effectiveness and patient
empowerment).
Cost-effectiveness
In order to assess the effectiveness of the care
innovation, a cost-effectiveness/cost-utility analysis will
Fig. 1 Design and flowchart of patient inclusion and follow-up
Table 1 Primary and secondary endpoints
Primary outcome [evaluated at 12 months’ post implant]
• Device acceptance (FPAS)
Secondary outcomes [evaluated at 12 and 24 months’ post implant]
• Health status (SF-12)
• Patient empowerment (ICD-EMPOWER)
• ICD concerns (ICDC)
• Anxiety (GAD-7)
• Depression (PHQ-9)
• Health status (KCCQ-12; for patients with heart failure only)
• Return to work
• Time to first ICD therapy defined as anti-tachycardia pacing, cardio
version or shock
• Time to first hospitalisation due to a cardiac cause
• Mortality
• Cost of intervention program
• Healthcare costs
• Labour market absence
• Cost-effectiveness (i.e., incremental cost gained per quality adjusted
life year (QALY) and burden on health care professionals (physicians and
nurses)a
aThis will be measured with the EQ-5D-5 L or captured from the patient’s
electronic health record (EHR; e.g. number of outpatient visits, admissions,
consultations with psychologists), and purpose-designed questions
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be performed, estimating the incremental costs and ef-
fects of the ACQUIRE-ICD care innovation and compar-
ing the two arms. The effect, in terms of changed/
improved health status/QoL (i.e., Quality Adjusted Life
Years), will be estimated using the EQ-5D. Patients will
fill in the EQ-5D questionnaire and the associated VAS
at different points in time (at inclusion, at 6-, 12-, and
24-months of follow up). The EQ-5D is a standardised
instrument for use as a measure of health outcome de-
veloped by health economists for this purpose. The
measure consists of a VAS, with patients rating their
health on a scale from 0 (worst imaginable health status)
to 100 (best imaginable health status), and a descriptive
system comprising five questions assessing the following
domains: Mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression [35]. Each question can
be scored as: having no problems (level 1), slight prob-
lems (level 2), moderate problems (level 3), severe prob-
lems (level 4), and extreme problems (level 5).
Subsequently, it is possible to estimate a utility score, a
single summary index derived on the basis of the EQ-5D
domains, with this information being useful in
cost-utility analysis.
Resource use and costs relating to the
ACQUIRE-ICD care innovation will be obtained pro-
spectively as costs related to individual participants
(variable costs) and the program (fixed costs). Health-
care resource use will be analysed based on data ex-
traction from national health registries for individual
participants. The costing period will be from the day
of entry into the trial and 12/24 months post im-
plantation. Resource data will include services used in
the hospital sector (National Patient Registry – som-
atic and psychiatry inpatient and outpatient contacts,
the Primary Care Registry and Registry of Prescription
Medication provided by the primary pharmacies).
These resources will be valued using current unit
costs (converted to €) based on national sources using
tariffs for diagnostic related groups (hospital service),
reimbursement fees (primary care service), transaction
costs (pharmaceutical services), current salaries, pro-
ject accounts and expert assessment.
Table 2 Patient-reported outcomes, cost-effectiveness and their assessment*
Construct Scale acronym Items T0 T6 T12 T24
Health status (generic) SF-12 12 X X X X
Health status (HF specific) KCCQ 12 X X X X
Depression PHQ-9 9 X X X X
Anxiety GAD-7 7 X X X X
Expectations to ICD treatment EXPECT-ICD 10 X
Expectations to use of platform/app EXPECT-APP 6 X
Experience with use of platform/app EXPERIENCE-APP 9 X X
ICD patient concerns ICDC 8 X X X X
ICD empowerment ICD-EMPOWER 14 X X X X
Illness perceptions B-IPQ 9 + 1 X
Adherence MMAS-8 8 X X X X
Type D personality DS14 14 X
Device acceptance FPAS 18 X X X X
Loneliness UCLA 3 X X X X
Cost of intervention program € Registry X X X X
Healthcare cost during observation period € Registry X X X X
Labour market absence € Registry X X X X
All-cause and cardiac-related mortality Deaths Registry X X X X
QALY EQ-5D-5 L + VAS 6 X X X X
Cost-effectiveness/utility (ICER) €/QALY – X X X X
Net-monetary benefit from health care and social perspective € - X X X X
T0 = Baseline; T6 = 6 months; T12 = 12 months; T24 = 24 months
*Both patients in the treatment group and usual care group will complete all measures at T0,T6,T12, and T24
B-IPQ Brief Illness Perceptions Questionnaire, DS14 Type D Scale, EQ-5D-5 L EuroQoL, EXPECT-ICD Expectations to ICD treatment questionnaire, EXPECT-APP
Expectations towards use of app, EXPERIENCE-APP Experience with use of app, FPAS Florida Patient Acceptance Survey, GAD Generalised Anxiety Disorder scale,
ICD-EMPOWER ICD Empowerment Scale, ICDC ICD Patients’ Concerns Questionnaire, KCCQ Kansas City Cardiomyopathy Questionnaire, MMAS-8 Morisky Medication
Adherence Scale, PHQ-9 Patient Health Questionnaire, QALY quality adjusted life year, SF-12 Short Form Health Survey, UCLA UCLA Loneliness Scale, VAS visual
analogue scale
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Effect, in terms of changed/increased life expectancy,
will be estimated based on extraction of vital status from
the National Death Registry. This registry includes date
of death and recorded casus of death if that has
occurred.
In addition, data from the National registry on Social
Transfer Payment (DREAM) will be obtained. This
registry will provide data on long-term sickness and re-
imbursement of lost productivity and provide a measure
of the absence from the labour market. This will only be
relevant for the period that participants are affiliated
with the labour market (i.e. until retirement age). The
registry will also provide information about early sick-
ness and voluntary retirement (i.e. before retirement
age). Difference between the participant groups will be
analysed using logistic or time-to-event regression
methods. Additional costs in terms of short-term prod-
uctivity costs due to absence from the work force (#
missed workdays patients; # missed workdays caregivers;
# hours care giving to patient) will be obtained through
participant questionnaires. Labour market absence will
be valued using age and gender stratified by average
gross wages obtained from Statistics Denmark.
Intervention
Usual care
Irrespective of the treatment condition that patients are
assigned to, all patients will receive usual care after
implantation. This includes usual clinical follow-up visits
in the outpatient ICD clinic by specialists and nursing
staff, their device being monitored remotely, and for
relevant patients, follow-up visits to other specialised
clinics for e.g. heart failure and arrhythmogenic
disorders.
Comprehensive interactive ACQUIRE-ICD eHealth
intervention
The ACQUIRE-ICD eHealth intervention is delivered
via the Liva Healthcare platform, which was developed
to help patients manage chronic diseases: https://liva-
healthcare.com/the-platform/. Liva is browser-based for
the health care professionals, with access to the platform
and its tools for patients via native solutions for smart-
phone (IOS and Android), tablet / iPad, or a website ap-
plication. The platform makes it possible for patients,
health care professionals and other stakeholders to ac-
cess, monitor and update personal health data in a se-
cure ISO 27001 environment. It allows for patients to
write personal messages to health care professionals and
vice versa, to set targets for behavioural change, to re-
ceive push messages to remind them to monitor lifestyle
and complete questionnaires, take action if targets are
not met, to engage in dialogues with fellow patients (via
the platform’s forum), and for health care professionals
to support patients with positive reinforcement and
multi-media contents (vodcasts, pdf-files, etc.), so that
patients can reach their goals [36].
The intervention consists of various components and
lasts 12 months. An overview of the components is pro-
vided in Table 3 and a more detailed description is pro-
vided below.
Goal-setting for behavioral change Via the platform,
patients can set goals and targets for change, such as ex-
ercising more, ensuring good sleep hygiene, eating more
healthily etc. The platform provides tailored feedback
and delivers positive reinforcement to patients via push
messages to encourage them to fulfill their goals. When
setting goals and targets for change, the SMART (Spe-
cific, Measureable, Achieveable, Realistic and Time-
bound) criteria are used, in order to keep patients
motivated and enhance patient success and outcomes,
while also recognising barriers to change, such as de-
pression [37].
Completion and monitoring of symptoms of depres-
sion and anxiety and health status Depression and
anxiety symptom and health status monitoring was in-
cluded in the intervention to educate patients about
their physical and mental health, as symptoms of depres-
sion and anxiety may serve as a barrier to behaviour
change and compliance. Without this awareness, pa-
tients’ endeavours to change are likely to fail, which may
decrease their motivation on the long-term, and influ-
ence their QoL and successful disease management.
Patients themselves indicate that psychological status is
one of the primary reasons for hospital readmission, with
unexpectedly few patients pointing to non-compliance as
the culprit [31]. Poor QoL and poor patient-rated health
status have been shown to predict poor prognosis and
mortality in patients with an ICD, despite state-of-the-art
treatment [38].
Table 3 Overview of the components of the ACQUIRE-ICD
intervention
• Goal-setting for behavioral change
• Monthly patient and clinician tracking and monitoring of symptoms
of depression (PHQ-8), anxiety (GAD-7) and health status (EQ-VAS) and
feedback
• Referral for psychological treatment based on value-based cognitive
behavioral therapy [only for patients with a positive screen on depression
and/or anxiety]
• Dialogues with nursing staff via the platform [1–3 months post
implant: once a week; 4–12 months: once a month; potential to obtain
extra feedback]
• Information provision and education (e.g. on ICD-related topics, anx
iety, depression, relaxation training, by means of multi-media contents,
such as quizzes, vodcasts of patients and health care professionals, etc.)
[examples of vodcasts are available here: https://helbredsprofilen.dk/en]
• Forum with online community network with “patients like me”
EQ-VAS EuroQoL visual analogue scale, GAD Generalised Anxiety Disorder
scale, PHQ Patient Health Questionnaire
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Patients will receive automatic prompts once a month
to complete the Patient Health Questionnaire (PHQ-8)
[39], the Generalised Anxiety Disorder scale (GAD-7)
[40], and the EuroQol visual analogue scale (EQ-VAS)
[41] to monitor their symptoms of depression and anx-
iety and health status, respectively. We chose to use the
8-item version of the PHQ rather than the 9-item ver-
sion, removing the item on suicidal ideation, as it is not
an accurate suicide screen and few cardiac patients en-
dorse this item [39]. The core symptoms of depression
as assessed with the PHQ-2 or PHQ-9 predict new onset
myocardial infarction and mortality [42]. Following com-
pletion of the questionnaires via the platform, the scores
are plotted into a graph and added to previously com-
pleted scores to generate a graphic summary showing
the evolution of scores over time. This allows patients
and nursing staff to routinely track patients’ status, flag
deteriorations early on that serve as cues for timely ac-
tion for patients and the ICD care team to discuss
whether action needs to be taken. An automatic re-
minder system is in place if patients do not complete the
questionnaires. Prior to the ACQUIRE-ICD trial, we
evaluated the experiences of patients and nursing staff
with health status monitoring in a feasibility study of pa-
tients with health failure. Although not all patients were
positive about monitoring, several patients and the nurs-
ing staff found it a useful tool and felt that it provided a
more true picture of how patients felt [43].
Patients will receive feedback from the nursing staff
every time they have completed the questionnaires. If
patients experience a decline ≥10 points (minimal clin-
ical importance difference) on EQ-VAS [41], nursing
staff will ask patients to reflect on the reasons for this
decline, and whether action needs to be taken. If patients
have an increased depression or anxiety score on the
PHQ-8 or GAD-7 score ≥ 10 (moderate symptoms),
nursing staff will refer the patient to the project’s psy-
chologists for online treatment.
Online psychological treatment An online treatment
program, based on value-based cognitive behavioral
therapy, was specifically developed for the study. The
psychologist will contact the patient who is referred by
the nursing staff and organise an intake over the phone.
During the intake – which is similar to the standard in-
take when the psychologist meets with the patient
face-to-face for the first time – the patient and the
psychologist discuss how the patient is doing and what
might have contributed to the onset of anxiety or de-
pression. If the patient feels impaired in his / her daily
living and consents to start with treatment, the
psychologist will initiate treatment that consists of 7
steps: (i) ICD and its impact; (ii) When one’s life
changes; (iii) The impact of thoughts on mood and
actions; (iv) Acceptance and values – living a valuable
life; (v) How does my daily life looks like?; (vi) Find a
good routine; (vii) To continue to develop and accept
stagnation or relapse. If the patient has already con-
tacted or is being seen by a psychologist, the patient will
not be offered parallel treatment in the ACQUIRE-ICD
study. In order to increase patient compliance with the
psychological treatment, patients are offered a phone
consultation mid-way (Step 3) and towards the end (Step
7) of the psychological treatment. If patients screen posi-
tive for anxiety and / or depression again, the patient
will again be referred to the psychologist.
Dialogues with nursing staff via the platform Dia-
logues via the platform with nursing staff happen asyn-
chronously. The patient can always enter data and see
on the platform when the nurse will send a message or
respond to the patient’s message. During the first
3 months of the intervention, the nurse will send weekly
messages, while in months 4–12, there will be one mes-
sage a month. Additional messages are allowed on a
need-to-basis.
Information provision and education To support be-
havioural change and to enhance patient motivation and
compliance, a toolbox is developed that contains educa-
tional multimedia content, such as vodcasts, links, text
and pictures, e.g. from ‘Helbredsprofilen’ https://helbred-
sprofilen.dk/en. The toolbox that was developed for the
ACQUIRE-ICD study has a broad focus with topics on
ICD treatment and management, self-care management,
resources for lifestyle changes and management (e.g. ex-
ercise tips), how to set realistic goals, how to keep up
motivation, and psychological and social issues, etc. The
toolbox also contains quizzes to inform and test patients’
knowledge and educate them about their device, heart
disease, psychological aspects and related topics. In
order not to overwhelm patients with too much or ir-
relevant information, nurses will send the contents of
the tool box to patients on the times scheduled for con-
tact via the nursing dialogues mentioned above accord-
ing to a pre-specified plan based on clinical experience
and when patients may need the information. These
supportive tools can be tailored to the individual needs
of patients.
Forum with online community network This feature
was included in the intervention, as evidence has shown
that online communities with peer-to-peer support from
“patients like me” that allow for patients to share their
stories and experiences is a successful addition to
web-based and digital solutions to facilitate behavioural
change and to provide social support, as it makes pa-
tients feel less alone [44]. The community is part of a
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mature community with more than 1000 members and
will undergo a mitosis after the inclusion of 50 patients
to strengthen the domain of ICD patients [45]. As there
is a known trade-off between moderation and control on
online patient communities and as we wanted to ensure
that patients feel free to express and share their thoughts
and experiences freely, we decided moderation only by a
“watchdog” – the community manager of the project
team – who follows the discussions on the forum and
redirect the conversation positively if it goes in a less
helpful manner [46].
Sample size calculation
Based on historical data from the Web-based Distress
Management Program for Implantable Cardioverter
Defibrillator (WEBCARE) patients that evaluated the ef-
fectiveness of an online behavioural treatment based on
problem-solving principles of cognitive behavioural ther-
apy [47, 48], we assume that a difference in device ac-
ceptance, as measured by the Florida Patient Acceptance
Survey, of 3 points at 12 months is the minimal clinically
relevant difference between treatment groups. We fur-
ther assume a standard deviation (SD) of 9 points. Tar-
geting the power analysis to these assumptions, with a
type I error of 0.05 (two-sided) and a power of 90%, 382
patients need to be evaluable for the primary endpoint.
To compensate for loss to follow-up (estimated at 20%),
we will aim to randomise a total of 478 patients (239 in
each arm).
Randomisation, blinding and treatment allocation
Patients are randomised in a 1:1 fashion to the
ACQUIRE-ICD eHealth intervention plus usual care
versus usual care alone, stratifying by center and heart
failure symptom severity (New York Heart Association
(NYHA) functional class I-II versus III-IV). A random
allocation sequence will be generated for each stratum
by an independent statistician. The sequence determines
the allocation for each subsequent patient. It is not pos-
sible to blind patients as to their study condition.
Ethics and safety considerations
The study will be conducted according to the principles of
the Declaration of Helsinki (64th WMA General
Assembly, Fortaleza, Brazil, October 2013). The study
protocol was submitted to the Regional Committees on
Health Research Ethics for Southern Denmark, who indi-
cated that according to Danish law about ethics related to
health research (§ 14, 1), ethical committee approval is not
required (VEK #S-20160063, June 13, 2016). The Danish
Data Protection Agency, via the umbrella scheme in the
Region of Southern Denmark (OUH #16/16935, June 21,
2016), has approved the project. Permission from the Da-
nish Health Authority is normally required if information
from patients’ EHRs need to be used for specific research
projects (health law § 46, 2). However, this is not required
if patients provide written consent that they are willing to
pass on this information, as is the case for ACQUIRE-ICD.
The trial has been registered on https://clinicaltrials.gov/
ct2/show/NCT02976961 [NCT02976961].
Statistical methods
General analyses
Data will be analysed according to the modified
intention-to-treat principle (i.e., all patients with a
12-month evaluation will be analysed as randomised).
Categorical variables will be summarised as n (%), con-
tinuous variables as min-max, mean (SD), and median.
All summaries will be reported by randomisation group.
Kaplan-Meier models will be used to estimate survival
functions related to time-to-event endpoints e.g. mortal-
ity, stratified by group. Regression analyses, linear, logis-
tic, and Cox proportional hazard will be used as
appropriate. The type of analysis will depend on the end-
point in question. The primary analysis will be a linear
regression of patients’ scores on the Florida Patient Ac-
ceptance Survey at 12 months including randomisation
group, baseline score and strata as factors and patients’
Florida Patient Acceptance Survey scores at baseline as
covariates. Potential confounders, apart from baseline
and stratification variables, identified by clinical consen-
sus, will be included in multivariable analyses when ap-
propriate (e.g. when performing sub-group analyses).
Additionally, a mixed effects model will be used to ana-
lyse the longitudinal change in mean device acceptance
scores on the Florida Patient Acceptance Survey while
adjusting for strata and baseline Florida Patient Accept-
ance Survey scores, incorporating random effects to
model the homogeneity within cluster and the correl-
ation within patient across time.
Subgroup analyses are planned for the primary end-
point with respect to: Type of device (CRT-D versus
ICD); symptomatic heart failure (NYHA class I-II (mild)
versus NYHA class III-IV (severe)); indication (primary
versus secondary prevention); sex (female versus male);
age (median split); depression status (PHQ score < 9 ver-
sus ≥10). All other subgroup analyses are explorative.
Cost-effectiveness analyses
The analysis of resource use and costs will be conducted
on individual participants’ aggregated cost measures dur-
ing the observation period (12/24 months) from the in-
clusion date for each individual participant. Cost data
are usually skewed and therefore require special analyt-
ical methods. The analysis will use the current standard
methodology for cost data (generalised regression as-
suming logistic link function and residuals with gamma
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distribution). Other methods will be explored to identify
the specifications that provide better fit to the data.
All-cause mortality, survival time, retirement and time
to retirement will be estimated from inclusion date until
death or censoring using appropriate statistical models
(Cox-regression or similar). All-cause and cardiac-related
mortality will also be used as measures of effect in the
cost-effectiveness analysis.
Quality-adjusted life years (QALYs) will be estimated
for each individual participant using all the available data
points from the EQ-VAS and EQ-5D instrument. The
EQ-5D scores will be converted to utility measures
(index ranging from 0 to 1) using the recommended al-
gorithm. Work is currently in progress to establish an
updated Danish value set. The analysis will be based on
the most updated value set at the time of analysis. Sensi-
tivity analysis will be conducted using different value
sets. The QALYs will include the area “under the curve”
of the different data points during the observation
period or until death.
The cost-effectiveness/cost-utility analysis generates
results in terms of incremental cost-effectiveness ratios
(ICERs). This analysis will use the data set of individual
participants’ monitarised resource use (cost) and QALY.
Mixed level difference-in-difference modelling will iden-
tify the average incremental cost and effect of the inter-
vention in comparison with the control group (the
ICER). By assuming a society treshold value for health
benefits (QALYs), the net monetary value of the inter-
vention will be analysed for the whole study population
(intention-to-treat and per-protocol) and subgroups of
the population. In order to assess the precision, the
ICERs sensitivity analysis (relating to structural uncer-
tainty) and bootstrapping methods (relating to statis-
tical/parameter uncertainty) will be performed. Both a
short-term and a long-term cost-effectiveness analysis
(CEA) will be performed. The short-term CEA will use
12/24 months’ time horizon (equivalent to the two-year
follow-up period) based on the data obtained through
the trial. The long-term CEA will have a lifetime time
horizon and will employ a purpose-built model of health
outcomes and resource use. The model will extend both
cost and effect data obtained from the trial using appro-
priate statistical methods. Analyses of the CEA will in-
clude probabilistic analyses, sensitivity analyses, and
scenario analyses. The main cost-effectiveness results
will be described as the incremental cost per QALY
gained and net-monetary benefit.
Before release of the data for analyses, the statistician
involved in the project will write a detailed statistical
analysis plan that will be subject to review and approval
by the steering committee. Data will be analysed using
STATA and R via OPEN Analyse, which is an analysis
environment (platform), where data can be stored and
processed securely on a server, which is in compliance
with the General Data Protection Regulation Directive
95/46/EC.
Study status
The study started recruitment in February 2017. By June
2018, 226 patients were recruited and randomised. We
expect to have recruited all patients by May 2019 and to
have completed the 12 months follow-up on May 2020
and the 24 months follow-up on May 2021.
Discussion
In the multi-center WEBCARE study that was con-
ducted in the Netherlands, we previously evaluated the
effectiveness of a simpler online behavioural treatment
that was focused on the treatment of anxiety and depres-
sion [47, 48]. To our knowledge, the ACQUIRE-ICD
study is the first study to evaluate the effectiveness and
cost-effectiveness of a comprehensive interactive eHealth
intervention in patients implanted with an ICD or
CRT-D. The intervention represents an innovative and
sustainable paradigm shift of care for patients with an
ICD, as it promotes and facilitates that patients become
active participants in the management of their own dis-
ease. It addresses the need for a more patient-tailored
disease-management approach with care being defined
by individual patients’ needs and preferences, and extra
resources being allocated to those patients who need it
the most. By systematically incorporating the patient
perspective and patient tools in routine clinical care, the
ACQUIRE-ICD study adheres to the recommendations
of the American Institute of Medicine for improving the
health care system of the twenty-first century to a sys-
tem that provides consistent and high-quality care that
is patient-centred. [49] As indicated in a recent editorial,
a patient-centred approach may be paramount in order
to advance the quality of care: “The practice of medicine
has evolved from supposition based to science- and
evidence-based, often extrapolating laboratory science to
the bedside. However, studies that include patient out-
comes are showing, with discomforting frequency, that
strategies once considered optimal often fall short of their
promise when success is defined as an improvement in
what the patient experiences” [50]. Relying on a
patient-centred approach, tools and outcomes may not
only lead to greater patient compliance, increase patient
treatment satisfaction and wellbeing but also improved
prognosis [51, 52].
The current study has some important strengths and
some limitations. One of the strengths of the current
study relates to the design as a multi-center national
study, as all 6 ICD implanting centers in Denmark are
participating and recruiting patients. In addition, study
endpoints include not only clinical outcomes and
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cost-effectiveness but also patient-reported outcomes, as
advocated both by the American Heart Association [53]
and the European Society of Cardiology [54], when
evaluating the effects of clinical trials. A limitation is
that it is not possible to blind patients to their condition
and whether they are randomised to the intervention
plus usual care versus usual care alone. Lack of blinding
may lead to bias and exaggeration of the effect size [55].
Conclusion
This article presents the study protocol of the
ACQUIRE-ICD study, a national multi-center rando-
mised controlled trial that will evaluate the effectiveness
of a comprehensive interactive eHealth intervention on
patient-reported and clinical outcomes and the
cost-effectiveness as add-on to usual care as compared
to usual care alone. The ACQUIRE-ICD care innovation
promotes and facilitates that patients become more ac-
tive participants in the management of their own dis-
ease, and as such addresses the need for a more
patient-centered disease-management approach.
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